NASDAQ:RLAY - Nasdaq - US75943R1023 - Common Stock - Currency: USD
Taking everything into account, RLAY scores 4 out of 10 in our fundamental rating. RLAY was compared to 560 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RLAY as it has an excellent financial health rating, but there are worries on the profitability. RLAY is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -38.76% | ||
ROE | -43.42% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 0.1 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 15.95 | ||
Quick Ratio | 15.95 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
2.95
+0.1 (+3.51%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 50.54 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.65 | ||
P/tB | 0.65 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -38.76% | ||
ROE | -43.42% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 36.93% | ||
Cap/Sales | 20.17% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 15.95 | ||
Quick Ratio | 15.95 | ||
Altman-Z | 0.1 |